Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.

Saved in:
Bibliographic Details
Title: Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Authors: Rugo HS; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA. hope.rugo@ucsf.edu., Campbell M; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Yau C; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Jo Chien A; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Wallace AM; University of California San Diego, San Diego, CA, USA., Isaacs C; Georgetown University, Washington, DC, USA., Boughey JC; Mayo Clinic, Rochester, MN, USA., Han HS; Moffitt Cancer Center, Tampa, FL, USA., Buxton M; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Clennell JL; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, CA, USA., Steeg K; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, CA, USA., Singhrao R; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Matthews JB; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Perlmutter J; Gemini Group, Ann Arbor, MI, USA., Fraser Symmans W; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hylton NM; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., DeMichele AM; University of Pennsylvania, Philadelphia, PA, USA., Yee D; University of Minnesota, Minneapolis, MN, USA., Van't Veer LJ; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA., Berry DA; Berry Consultants, LLC, Houston, TX, USA., Esserman LJ; University of California San Francisco, Box 1710, San Francisco, CA, 94143, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Feb; Vol. 209 (3), pp. 487-492. Date of Electronic Publication: 2024 Dec 03.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1573-7217
DOI:10.1007/s10549-024-07555-9